Christopher W. Ryan - Concepedia

Author

Christopher W. Ryan

Oregon Health & Science University ORCID

Also Known As

C Ryan, C W Ryan, C. RYAN, C. Ryan, C. W. Ryan, C.W. Ryan, CHRISTOPHER W. RYAN, Christopher Ryan, Christopher W Ryan, Christopher W. Ryan

257

Publications

9.5K

Citations

H-Index

Concepts

All Affiliations

Oregon Health & Science University University of Chicago Dana-Farber Cancer Institute Northwestern University Fred Hutch Cancer Center

About

Christopher W. Ryan is an author at Oregon Health & Science University specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	23	38	2.6K
2	Health Sciences	8	8	199
3	Engineering	2	2	51
4	Education	1	1	10
5	Natural Sciences	1	1	37

Christopher W. Ryan

101

Publications

8.7K

Citations

H-Index

Page 1

	Year	Citations
Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033 Charles D. Blanke, Cathryn Rankin, George D. Demetri, Journal of Clinical Oncology	2008	1.1K
Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group Michael C. Heinrich, Kouros Owzar, Christopher L. Corless, Journal of Clinical Oncology	2008	649
Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial William D. Tap, Hans Gelderblom, Emanuela Palmerini, The Lancet Surgical OncologyOncologyMedicineRandomised Phase 3Pathology	2019	454
Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial Andrew J. Armstrong, Susan Halabi, Tim Eisen, The Lancet Oncology UrologyGenitourinary CancerMedicineRandomised Phase 2Cancer Treatment	2016	420
A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors Sandip Pravin Patel, Megan Othus, Young Kwang Chae, Clinical Cancer Research	2020	317
Double-Blinded Randomized Study of High-Dose Calcitriol Plus Docetaxel Compared With Placebo Plus Docetaxel in Androgen-Independent Prostate Cancer: A Report From the ASCENT Investigators Tomasz M. Beer, Christopher W. Ryan, Peter Venner, Journal of Clinical Oncology	2007	309
Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial William D. Tap, Zsuzsanna Pápai, Brian A. Van Tine, The Lancet Oncology MedicineRandomised Phase 3Metronomic TherapyTh Cr-406/sarc021Evofosfamide Versus Doxorubicin	2017	293
Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America Walter M. Stadler, Robert A. Figlin, David F. McDermott, Cancer	2010	253
Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma Lara E. Davis, Vanessa Bolejack, Christopher W. Ryan, Journal of Clinical Oncology	2019	251
A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancer Joshi J. Alumkal, Rachel Slottke, Jacob Schwartzman, Investigational New Drugs UrologyMedicinePathologyPhase Ii StudyProstatic Disease	2014	216

Page 1